acta diurna · run record
2026-09-22-medtech
22 September 2026 ·partial
| # | stage | model | verdict | retries | notes | cost |
|---|---|---|---|---|---|---|
| 01 | nuncio | deepseek/deepseek-v4-flash | — | — | rss:FierceBiotech failed (Cannot convert object to primitive value) [optional] | rss:Fierce Pharma failed (Cannot convert object to primitive value) [optional] | 4 gathered stories already covered by the Specola — excluded: "STAT+: Radiopharma companies merge after one receives surprise FDA rejection", "Addiction clinics see rising cases of kratom and 7-OH withdrawal", "Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial", "Beacon says gene therapy succeeds in key trial of rare eye disease XLRP" | $0.0003 |
| 02 | bulletins | anthropic/claude-sonnet-5 | — | — | "Congress pushes back on plan for political appointees to review NIH grants": pass (0 redispatch) | "Trump's newest vaccine demands repeat old misinformation": pass (1 redispatch) | "Lilly's breast cancer combo wins FDA approval": pass (0 redispatch) | "What a vote on Grail's cancer detection test could mean for patients and regulators": spiked (2 redispatch) | "Social media bans are passing around the world. How will we know if they help teens?": pass (1 redispatch) | $0.0995 |
| 03 | dispatch | anthropic/claude-sonnet-5 | pass | — | $0.1221 | |
| 04 | rounds | anthropic/claude-sonnet-5 | pass | — | $0.0386 | |
| 05 | illuminate-rounds | — | — | — | skipped: no FAL_KEY — "The Courtier Who Wanted a Seat at the Bedside" publishes without a plate | $0.0000 |
| 06 | spikes | — | — | — | SPIKED "What a vote on Grail's cancer detection test could mean for patients and regulators": The bulletin identifies the test as “known as Galleri,” but the supplied source material only describes it as Grail's blood test for cancer and does not provide that name.; The statement that FDA advisory committees “typically review evidence on a product's safety and effectiveness” is general background not supported by the supplied source material and is presented as though it explains this meeting's review.; The attribution “STAT News framed the upcoming proceedings” as having implications for “patients and for regulators” goes beyond the supplied summary; those terms appear in the headline, but the provided material does not establish the article's specific framing or analysis.; The closing claim that the surge “reflects investor interest in the regulatory process now underway” infers investor motivation and describes a regulatory process beyond the supported fact that shares rose after FDA documents were posted ahead of a committee meeting. | — |
| the day's wage | $0.2605 | |||||